Skip to content
AnalystLens

Elevance HealthELV

Legal name
Elevance Health, Inc.
Industry
Hospital & Medical Service Plans
Exchange
NYSE

Stock Price $ELV

You are here#22 of 59 in Healthcare by market cap

Filing record · 2016–202610-K1110-Q348-K134

ELV filed 11 annual reports (10-K), 34 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Deal closed8-K · Apr ’22Apr ’22
  4. Leadership change8-K · Dec ’25Dec ’25
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  1. $199.13B
YoY changeLargest recent move+16.9%in FY20Latest +12.5%

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →

Elevance Health Financial Overview 2021–2025

Updated Nov 3, 2026

Elevance Health drove a massive 12.8% revenue surge to $197.6 billiona in FY2025, yet shareholders' net income simultaneously slid by 5.3% to $5.66 billion. This persistent disconnect between top-line expansion and bottom-line contraction highlights the core investment reality for the healthcare giant: while the company commands immense scale and pricing power, surging medical cost trends and Medicaid attrition are actively squeezing profitability.

Despite these recent margin pressures, the company’s structural growth arc remains formidable, with total operating revenue climbing from $136.9 billion in FY2021 to $197.6 billionb in FY2025. This expansion was largely fueled by Medicare Advantage growth, aggressive premium rate hikes, and the rapid scale of its CarelonRx pharmacy unit, which delivered a 20.7% revenue jump in FY2025. However, operational headwinds are clearly visible in the company's total medical membership, which essentially flatlined from 45.4 million members in FY2021 to 45.2 million in FY2025 after weathering a severe 15.1% plunge in Medicaid enrollment during FY2024 due to government eligibility redeterminations.

To buffer these operational headwinds, management leaned heavily into share repurchases, reducing outstanding shares to support an EPS of $25.21c for FY2025. At the close of FY2025, the market priced this mixed operational picture cautiously. Elevance Health traded at just 13.9x earnings with a stock price of $350.55, valuing the enterprise at a $77.4 billion market capitalization.

Recent Developments (Q2 and Q3 2026)

A $935 milliond Medicare Advantage risk adjustment accrual defined Q2 2026, then closed out with a CMS resolution and no sanctions. Net income for the first half fell 17.8% to $3.23 billion. Health Benefits operating gain dropped 42.6% to $896 million in Q2, as the benefit expense ratio rose 80 bps to 89.7%. Recovery showed in Q3 2026: diluted EPS rose 17.9% to $6.27, and Carelon operating gain rose 17%. Management raised full-year diluted EPS guidance to at least $22.00 and adjusted EPS to at least $29.00, from $19.85 and $26.75 in June.

Bull case: guidance has risen twice, operating cash flow is up 78.6% to $7.51 billione for nine months, and the CMS matter is closed. Bear case: revenue grew only 1.8%, membership fell to 44.88 million, and Government medical cost trend still pressures margins. The stock traded at 17.2x earnings as of the Q3 2026 report date (October 20, 2026), up from the prior year-end multiple, not today's.

What to watch: Health Benefits margin recovery from 2.1%; membership trends in Medicaid and Medicare Advantage

Recent SEC Filings

  1. 8-KElevance Health 8-K Report, Regulation FD Disclosure (Nov 10, 2026)Elevance Health, Inc. (ELV) has released an 8-K filing on November 10, 2026, primarily to reaffirm its full-year 2026 financial guidance to investors and analysts. The company expects shareholders' earnings to be at least $22.00 per diluted share. This figure includes approximately $7.00 per diluted share attributable to net unfavorable items. Excluding these specific items, Elevance Health projects adjusted shareholders' earnings to be at least $29.00 per diluted share, a projection that does not incorporate further adjustments beyond those already accounted for in the third quarter of 2026. Furthermore, the company reaffirmed its guidance for the full-year 2026 benefit expense ratio, which is expected to be 90.2%, with a tolerance of plus or minus 50 basis points. This communication is intended to provide clarity and reinforce the company's financial outlook to the investment community amidst ongoing discussions.
  2. 8-KElevance Health 8-K Report, Financial Results (Oct 21, 2026)Elevance Health, Inc. (ELV) has reported its third quarter 2026 financial results, demonstrating a slight increase in operating revenue to $50.4 billion, up 0.7% year-over-year. The company's performance exceeded expectations, leading to an upward revision of its full-year 2026 guidance for both diluted EPS and adjusted diluted EPS. This positive outlook is supported by improved operating performance and a notable net non-operating benefit recognized in the quarter. The company highlighted increased operating cash flow and continues to invest in capabilities aimed at enhancing the member experience, strengthening its competitive position, and driving long-term growth. The Health Benefits segment saw revenue growth driven by premium yields and service fees, although membership declined in key areas like Medicare Advantage and Medicaid. Conversely, the Carelon segment, encompassing CarelonRx and Carelon Services, experienced robust revenue and operating gain growth, underscoring the strength of its pharmacy and services offerings.
  3. 8-KElevance Health 8-K Report, Regulation FD Disclosure (Sep 10, 2026)Elevance Health, Inc. (ELV) has filed an 8-K report on September 10, 2026, to reaffirm its financial guidance for the full year 2026. The company expects shareholders' earnings to be at least $20.10 per diluted share, which includes approximately $6.90 per diluted share related to net unfavorable items. Excluding these specific items, Elevance Health maintains its adjusted shareholders' earnings expectation of at least $27.00 per diluted share. This guidance does not account for any additional adjustment items beyond those already reported in the second quarter of 2026. Furthermore, the company is reaffirming its full-year 2026 guidance for the benefit expense ratio, projecting it to be 90.2%, with a permissible range of plus or minus 50 basis points. This reaffirmation indicates management's confidence in their ability to manage costs and maintain projected profitability within the specified parameters. Investors should note that the information provided is forward-looking and subject to the risks and uncertainties outlined in the filing.
  4. 8-KElevance Health 8-K Report, Financial Results (Jul 15, 2026)Elevance Health (ELV) reported second quarter 2026 results on July 15, 2026, with operating revenue of $49.8 billion, up 0.8% year over year, and diluted EPS of $6.71 (down 13.1% from $7.72). Adjusted diluted EPS was $7.45, down from $8.84, and the company said results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit. The benefit expense ratio rose 80 basis points to 89.7%, driven by elevated medical cost trend in Government businesses, partially offset by better Individual ACA performance. Operating gain fell 27.3% to $1.8 billion, with Health Benefits operating margin compressing to 2.1% from 3.8%. Carelon was the bright spot, with revenue up 6% to $19.2 billion and CarelonRx and Carelon Services growing. Management raised full-year 2026 guidance: diluted EPS to at least $20.10 and adjusted diluted EPS to at least $27.00, and raised operating cash flow guidance to at least $6.0 billion. The company also reaffirmed its target of at least 12% adjusted EPS growth in 2027 off its 2026 baseline, while accelerating targeted investments in medical cost management, member experience, provider connectivity, operating efficiency, and Carelon's value-based solutions. The adjusted operating expense ratio rose 100 basis points to 11.0%, reflecting these investments. Investors should note that the full-year EPS gap between GAAP and adjusted figures is large, driven by a $935 million (about $4.27 per share) accrual tied to a February 27, 2026 CMS notice on historical Medicare Advantage risk adjustment data, along with intangible amortization and investment-related items. On the balance sheet and cash flow side, six-month operating cash flow was $6.2 billion, though Q2 operating cash flow of $1.9 billion was affected by timing of a state Medicaid pass-through payment. Medical membership declined 1.5% year over year to 44.9 million, mainly from Medicare Advantage, Medicaid, and Individual ACA attrition and a commercial fee-based customer transition. The company repurchased $234 million of stock in the quarter, paid a $1.72 per share dividend, and retains about $5.3 billion in buyback authorization. The third-quarter dividend of $1.72 is payable September 25, 2026.
  5. 8-KElevance Health 8-K Report, Regulation FD Disclosure (Jun 10, 2026)Elevance Health, Inc. (ELV) issued an 8-K filing on June 10, 2026, to reaffirm its financial guidance for the full year 2026. The company expects shareholders' earnings per diluted share to be at least $19.85, which includes approximately $6.90 per diluted share from net unfavorable items. Excluding these items, the adjusted shareholders' earnings are projected to be at least $26.75 per diluted share, consistent with expectations set in the first quarter of 2026. This guidance does not incorporate any further adjustment items beyond those already reported. Additionally, Elevance Health is reiterating its full-year 2026 guidance for the benefit expense ratio, which is expected to be 90.2% plus or minus 50 basis points. This filing serves as a communication with investors and analysts, confirming the company's financial outlook and operational expectations for the remainder of the fiscal year.
View all 8-K filings →